Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0N4OW
|
|||
Former ID |
DAP000018
|
|||
Drug Name |
Vasopressin
|
|||
Synonyms |
Leiormone; Pitressin; Pituitrin; Tonephin; Vasopressina; Vasopressine; Vasopressins; Vasopressinum; American Pharmaceutical Brand of Vasopressin; American Regent Brand of Vasopressin; Antidiuretic Hormones; Antidiuretic hormone; Beta Hypophamine; Inyectable de vasopresina; Monarch Brand of Vasopressin; Solute injectable de vasopressine; Vasopressin Monarch Brand; Vasopressin injection; Vasopressina [DCIT]; Vasopressini injectio; ADH (hormone); Beta-Hypophamine; Inyectable de vasopresina [INN-Spanish]; Pitressin (TN); Solute injectable de vasopressine [INN-French]; Vasopressin (USP); Vasopressini injectio [INN-Latin]; Parke-Davis Brand of Vasopressin (USP); Vasopressin (JP15/USP)
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Diabetes insipidus [ICD-11: 5A61.5; ICD-10: E23.2] | Approved | [1], [2] | |
Enuresis [ICD-11: 6C00; ICD-10: F98.0] | Approved | [1], [2] | ||
Polyuria [ICD-11: MF55; ICD-10: R35] | Approved | [1], [2] | ||
Therapeutic Class |
Vasoconstrictor Agents
|
|||
Company |
Astellas Pharma
|
|||
Structure |
Download2D MOL |
|||
Formula |
C46H65N15O12S2
|
|||
Canonical SMILES |
C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N
|
|||
InChI |
1S/C46H65N15O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
|
|||
InChIKey |
KBZOIRJILGZLEJ-LGYYRGKSSA-N
|
|||
CAS Number |
CAS 113-79-1
|
|||
PubChem Compound ID | ||||
PubChem Substance ID | ||||
ChEBI ID |
CHEBI:34543
|
|||
ADReCS Drug ID | BADD_D02339 | |||
SuperDrug ATC ID |
H01BA01
|
|||
SuperDrug CAS ID |
cas=000050577
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Vasopressin V2 receptor (V2R) | Target Info | Agonist | [3] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Vasopressin-regulated water reabsorption | ||||
Pathwhiz Pathway | Vasopressin Regulation of Water Homeostasis | |||
Pathway Interaction Database | Arf6 trafficking events | |||
Reactome | Vasopressin-like receptors | |||
G alpha (s) signalling events | ||||
Vasopressin regulates renal water homeostasis via Aquaporins | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Regulation of Water Balance by Renal Aquaporins | ||||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2168). | |||
REF 2 | New topics in vasopressin receptors and approach to novel drugs: research and development of conivaptan hydrochloride (YM087), a drug for the treatment of hyponatremia. J Pharmacol Sci. 2009 Jan;109(1):53-9. | |||
REF 3 | Vasopressin receptors: structure/function relationships and signal transduction in target cells. J Soc Biol. 2005;199(4):351-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.